Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Memorial Sloan Kettering Cancer Center · 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
multiplemyeloma
multiple myeloma, monoclonal gammopathy of renal significance, cyclophosphamide, bortezomib, dexamethasone, daratumumab, 22-424, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 839125
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.